Chemomab Therapeutics (CMMB) Cash & Current Investments (2017 - 2025)

Chemomab Therapeutics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $10.4 million for Q4 2025.

• Quarterly Cash & Current Investments rose 68.64% year-over-year to $10.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.4 million (up 68.64% YoY) and the FY2025 annual result came in at $10.4 million, up 68.64% from the prior year.
• Cash & Current Investments was $10.4 million for Q4 2025 at Chemomab Therapeutics, up from $10.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $66.9 million in Q2 2021 and bottomed at $6.1 million in Q4 2024.
• A 5-year average of $29.3 million and a median of $20.4 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments surged 849.59% — and 2023, when it sank 76.52%.
• Chemomab Therapeutics' Cash & Current Investments stood at $15.2 million in 2021, then soared by 162.7% to $39.9 million in 2022, then tumbled by 76.52% to $9.4 million in 2023, then tumbled by 34.38% to $6.1 million in 2024, then soared by 68.64% to $10.4 million in 2025.
• Business Quant data shows CMMB's Cash & Current Investments at $10.4 million in Q4 2025, $10.1 million in Q3 2025, and $9.5 million in Q2 2025.